Targeted Therapy for Cancer. The Gastrointestinal Stromal Tumor Model

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 805-821

  Balachandran, Vinod P ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; Imatinib; KIT; Sarcoma; Tyrosine kinase

Indexed keywords

DOXORUBICIN; IMATINIB; IMMUNOMODULATING AGENT; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; REGORAFENIB; SUNITINIB;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE C KIT; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR GENE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

GASTROINTESTINAL STROMAL TUMOR; IMATINIB; KIT; SARCOMA; TYROSINE KINASE;

ANIMALS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84883558296     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.06.001     Document Type: Review

References (119)

1. Ducimetiere F., Lurkin A., Ranchere-Vince D., et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011, 6(8):e20294.
2. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005, 103(4):821-829.
3. Steigen S.E., Eide T.J. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 2006, 114(3):192-200.
4. Mucciarini C., Rossi G., Bertolini F., et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007, 7:230.
5. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231(1):51-58.
6. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEngl J Med 2002, 347(7):472-480.
7. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
8. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
9. Kindblom L.G., Remotti H.E., Aldenborg F., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152(5):1259-1269.
10. Sarlomo-Rikala M., Kovatich A.J., Barusevicius A., et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998, 11(8):728-734.
11. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96(3):925-932.
12. Tuveson D.A., Willis N.A., Jacks T., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20(36):5054-5058.
13. Corless C.L., McGreevey L., Haley A., et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160(5):1567-1572.
14. Agaimy A., Wunsch P.H., Hofstaedter F., et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007, 31(1):113-120.
15. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61(22):8118-8121.
16. Sommer G., Agosti V., Ehlers I., et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003, 100(11):6706-6711.
17. Rubin B.P., Antonescu C.R., Scott-Browne J.P., et al. Aknock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 2005, 65(15):6631-6639.
18. Nakatani H., Kobayashi M., Jin T., et al. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci 2005, 96(2):116-119.
19. Tarn C., Skorobogatko Y.V., Taguchi T., et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006, 66(10):5477-5486.
20. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. JClin Oncol 2006, 24(29):4764-4774.
21. Rossi F., Ehlers I., Agosti V., et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006, 103(34):12843-12848.
22. Rubin B.P., Heinrich M.C., Corless C.L. Gastrointestinal stromal tumour. Lancet 2007, 369(9574):1731-1741.
23. Chi P., Chen Y., Zhang L., et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010, 467(7317):849-853.
24. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710.
25. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125(3):660-667.
26. Kang H.J., Nam S.W., Kim H., et al. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005, 24(6):1066-1074.
27. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., et al. Agreat majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004, 84(7):874-883.
28. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47(10):853-859.
29. Hostein I., Faur N., Primois C., et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010, 133(1):141-148.
30. Janeway K.A., Kim S.Y., Lodish M., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011, 108(1):314-318.
31. Pantaleo M.A., Astolfi A., Indio V., et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. JNatl Cancer Inst 2011, 103(12):983-987.
32. Lasota J., Wang Z., Kim S.Y., et al. Expression of the receptor for type I insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol 2013, 37(1):114-119.
33. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011, 11(12):865-878.
34. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. NEngl J Med 2001, 344(14):1052-1056.
35. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358(9291):1421-1423.
36. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. JClin Oncol 2008, 26(4):626.
37. Le Cesne A., Ray-Coquard I., Bui B.N., et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010, 11(10):942-949.
38. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. JClin Oncol 2007, 25(13):1760-1764.
39. Van den Abbeele A.D., Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38(Suppl 5):S60-S65.
40. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005, 7(4):307-311.
41. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. JClin Oncol 2007, 25(13):1753-1759.
42. Antonescu C.R. The GIST paradigm: lessons for other kinase-driven cancers. JPathol 2011, 223(2):251-261.
43. Joensuu H., DeMatteo R.P. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012, 63:247-258.
44. DeMatteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9669):1097-1104.
45. Joensuu H., Eriksson M., Sundby Hall K., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAm Med Assoc 2012, 307(12):1265-1272.
46. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005, 353(16):1673-1684.
47. McAuliffe J.C., Hunt K.K., Lazar A.J., et al. Arandomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16(4):910-919.
48. Doyon C., Sideris L., Leblanc G., et al. Prolonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor results of a phase II trial. Int J Surg Oncol 2012, 2012:761576.
49. Wang D., Zhang Q., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012, 19(4):1074-1080.
50. DeMatteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112(3):608-615.
51. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. JClin Oncol 2002, 20(18):3898-3905.
52. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003, 106(6):887-895.
53. Martin J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). JClin Oncol 2005, 23(25):6190-6198.
54. Gold J., Gönen M., Gutiérrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10:1045-1052.
55. Rossi S., Miceli R., Messerini L., et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011, 35(11):1646-1656.
56. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11(11):4182-4190.
57. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. JClin Oncol 2003, 21(23):4342-4349.
58. Chen L.L., Trent J.C., Wu E.F., et al. Amissense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004, 64(17):5913-5919.
59. Wakai T., Kanda T., Hirota S., et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004, 90(11):2059-2061.
60. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128(2):270-279.
61. Grimpen F., Yip D., McArthur G., et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 2005, 6(9):724-727.
62. Wardelmann E., Thomas N., Merkelbach-Bruse S., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6(4):249-251.
63. Koyama T., Nimura H., Kobayashi K., et al. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment. Gastric Cancer 2006, 9(3):235-239.
64. Liegl B., Kepten I., Le C., et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. JPathol 2008, 216(1):64-74.
65. Lim K.H., Huang M.J., Chen L.T., et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol 2008, 25(2):207-213.
66. Nishida T., Kanda T., Nishitani A., et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008, 99(4):799-804.
67. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12(6):1743-1749.
68. Loughrey M.B., Waring P.M., Dobrovic A., et al. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin Cancer Res 2006, 12(20 Pt 1):6205-6206. [author reply: 6206-7].
69. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
70. Le Cesne A., Blay J.Y., Bui B.N., et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010, 46(8):1344-1351.
71. Benjamin R.S., Schoffski P., Hartmann J.T., et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011, 68(1):69-77.
72. Joensuu H., De Braud F., Grignagni G., et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011, 104(11):1686-1690.
73. Demetri G.D., Reichardt P., Kang Y.K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(9863):295-302.
74. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007, 245(3):347-352.
75. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. JClin Oncol 2006, 24(15):2325-2331.
76. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007, 245(3):341-346.
77. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12(4):237-251.
78. Ménard C., Blay J.Y., Borg C., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009, 69(8):3563-3569.
79. Balachandran V.P., Cavnar M.J., Zeng S., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17(9):1094-1100.
80. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. JClin Oncol 2006, 24(26):4340-4346.
81. Beadling C., Jacobson-Dunlop E., Hodi F.S., et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14(21):6821-6828.
82. Carvajal R.D., Antonescu C.R., Wolchok J.D., et al. KIT as a therapeutic target in metastatic melanoma. JAm Med Assoc 2011, 305(22):2327-2334.
83. Kemmer K., Corless C.L., Fletcher J.A., et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004, 164(1):305-313.
84. Pedersini R., Vattemi E., Mazzoleni G., et al. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007, 8(11):1039-1040.
85. Johnson B.E., Fischer T., Fischer B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9(16 Pt 1):5880-5887.
86. Boldrini L., Ursino S., Gisfredi S., et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 2004, 10(12 Pt 1):4101-4108.
87. Tamborini E., Bonadiman L., Greco A., et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 2004, 10(3):938-943.
88. Strobel P., Hartmann M., Jakob A., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. NEngl J Med 2004, 350(25):2625-2626.
89. Simon M.P., Pedeutour F., Sirvent N., et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997, 15(1):95-98.
90. Rutkowski P., Van Glabbeke M., Rankin C.J., et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. JClin Oncol 2010, 28(10):1772-1779.
91. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAm Med Assoc 2003, 290(16):2149-2158.
92. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350(21):2129-2139.
93. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
94. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
95. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. NEngl J Med 2005, 353(2):123-132.
96. Cohen E.E., Davis D.W., Karrison T.G., et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009, 10(3):247-257.
97. Pautier P., Joly F., Kerbrat P., et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 2010, 116(2):157-162.
98. Rini B.I. Lapatinib therapy for patients with advanced renal cell carcinoma. Nat Clin Pract Oncol 2008, 5(11):626-627.
99. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEngl J Med 2004, 351(4):337-345.
100. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. JClin Oncol 2010, 28(31):4706-4713.
101. Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315):596-599.
102. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364(26):2507-2516.
103. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344(11):783-792.
104. Oxnard G.R., Binder A., Janne P.A. New targetable oncogenes in non-small-cell lung cancer. JClin Oncol 2013, 31:1097-1104.
105. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. NEngl J Med 2005, 353(2):172-187.
106. Kurzrock R., Sherman S.I., Ball D.W., et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. JClin Oncol 2011, 29(19):2660-2666.
107. Wells S.A., Robinson B.G., Gagel R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. JClin Oncol 2012, 30(2):134-141.
108. Lam E.T., Ringel M.D., Kloos R.T., et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. JClin Oncol 2010, 28(14):2323-2330.
109. Sawaki A., Nishida T., Doi T., et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011, 117:4633-4641.
110. Cauchi C., Somaiah N., Engstrom P.F., et al. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 2012, 69(4):977-982.
111. Reichardt P., Blay J.Y., Gelderblom H., et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012, 23(7):1680-1687.
112. Demetri G.D., Lo Russo P., MacPherson I.R., et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009, 15(19):6232-6240.
113. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
114. Italiano A., Cioffi A., Coco P., et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 2012, 19(5):1551-1559.
115. Park S.H., Ryu M.H., Ryoo B.Y., et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012, 30(6):2377-2383.
116. George S., Wang Q., Heinrich M.C., et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. JClin Oncol 2012, 30(19):2401-2407.
117. Soria J.C., Massard C., Magne N., et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 2009, 45(13):2333-2341.
118. Joensuu H., De Braud F., Coco P., et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008, 19(1):173-177.
119. Heinrich M.C., Griffith D., McKinley A., et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012, 18(16):4375-4384.